

Digital Diagnostics, Orbis International to enhance eye care in Bangladesh

15 June 2021 | News

A study that will bring high-quality disease detection to communities in Bangladesh



Digital Diagnostics, developers of IDx-DR, an FDA De Novo-cleared autonomous AI system for the detection of diabetic retinopathy (DR) and diabetic macular edema (DME), and Orbis International, the influential nonprofit dedicated to fighting avoidable blindness around the world, have partnered on a study that will bring high-quality disease detection to communities in Bangladesh.

"There are over 8 million people with diabetes in Bangladesh, many of whom don't have access to the care they need, such as routine diabetic eye exams," said Michael Abramoff, MD, PhD, Founder and Executive Chairman of Digital Diagnostics. "We are excited to partner with Orbis to study the impact autonomous AI can have on physician productivity while also helping increase access, and lower cost for patients."

The study will focus on the implementation of IDx-DR to evaluate patients in Northern Bangladesh for diabetic retinopathy using autonomous AI to assess if the technology increases the number of patients tested for DR, and in turn, empower local physicians to make a greater impact in their community.

"As autonomous AI innovation continues to gain acceptance in healthcare, we at Orbis have the exciting challenge of getting to choose our partners from an elite field of innovators," said Dr. Hunter Cherwek, Orbis International's Vice President of Clinical Services and Technologies. "After careful consideration, we chose to implement IDx-DR's highly validated system for this study, to help us empower local doctors in Northern Bangladesh, as they work to improve patient outcomes and save their patients' vision."